Navigation Links
PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
Date:9/21/2010

SOUTH PLAINFIELD, N.J., Sept. 21 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF).  The goal of the FDA's OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO)

"We are pleased to receive this grant from the FDA to support our ongoing development of ataluren for the treatment of nonsense mutation cystic fibrosis," stated Stuart W. Peltz, Ph.D., President and Chief Executive Officer of PTC Therapeutics.  "In addition to recognizing the potential of ataluren, this grant reflects PTC's long-standing commitment to developing new treatments for patients with rare genetic disorders that severely impact survival and quality of life."

The Phase 3 trial will enroll approximately 200 patients at research centers in North America, Europe and Israel.  The primary goal of the study is to evaluate whether ataluren can improve lung function as measured by forced expiratory volume (FEV1).  Other outcome measures will evaluate whether ataluren can decrease lung infections, reduce the frequency of cough and improve patient-reported quality of life.  Patients are randomized to receive either ataluren (40 mg/kg) or placebo daily for 48 weeks.  Study candidates include patients who are at least six years of age and have CF due to a nonsense mutation.

Patients with CF lack adequate levels of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a chloride channel necessary for norm
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
5. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
6. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Arno Therapeutics Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Pipette.com has added ... to their comprehensive portfolio of Eppendorf products. , The ... purchase a Centrifuge 5424/5424 R and receive the following:, ... Eppendorf Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... 2015 Diagenode, Inc., a leading ... Bioruptor® and complete solutions for epigenetics research, recently ... alleviating the need for manual processing. The new ... ChIP of histones or transcription factors and a ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... ... ... - Interaction of nimotuzumab with EGFRvIII, a mutant form of EGF receptor frequently ... , , ...
... LONDON and ... Matrix,Corporate Capital ("Matrix") and PharmaVentures Limited ("PharmaVentures"),today ... ("MOU") covering,strategic transactions in the biotech, pharmaceutical and ... identify licensing, buyout, investment,IPO and consolidation opportunities which ...
... Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients ... ... , ... ...
Cached Biology Technology:YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 2YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 3YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 4YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 5YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 6YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 7Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU) 2Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU) 3Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU) 4NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 2NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 3NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 4NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 5NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 6NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 7NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 8NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 9NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 10NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 11NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 12NAVIGATOR Shows Valsartan Delayed Progression to Type 2 Diabetes in At-Risk Cardiovascular Patients With Impaired Glucose Tolerance 13
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... LAFAYETTE, Ind. - Warmer, drier summers and extreme weather ... especially troublesome - possibly fatal - for walnut trees, ... years, Douglass Jacobs, a professor of forestry and natural ... Jacobs who is now a research scientist in the ...
... effects of climate warming on biodiversity pose a serious conservation ... Science .,Marine life may need to relocate faster than ... timing of major life cycle events. This challenges previous thinking ... than species on land because of slower warming in the ...
... of Cambridge study, which set out to investigate DNA methylation ... lifestyle and our health, has now mapped the link in ... collected greatly benefits a field that is still in its ... the researchers were, even 18 months ago. Researcher ...
Cached Biology News:Walnut trees may not be able to withstand climate change 2No plain sailing for marine life as climate warms 2No plain sailing for marine life as climate warms 3Environment and diet leave their prints on the heart 2
... Compliant software for JASCO HPLC systems. , Integrated Instrument Control ... EZChrom Elite ... for JASCO HPLC systems. This provides a completely integrated system to ... with each run. , ...
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
... SilverSNAP Stain for Mass Spectrometry Applications ... spectrometry (MS) has emerged as a powerful ... of 2-D gels is now an important ... that leads ultimately to identification of specific ...
... Protein Extraction Reagent is a ... that means no scraping, no ... With M-PER Reagent, rapid lysis ... at room temperature, yielding 25% ...
Biology Products: